MORPHEUS-LIVER is a phase 1b/2 open label, multicenter randomized umbrella study assessing atezolizumab and bevacizumab in combination with various investigational therapies in patients with unresectable HCC and no prior systemic therapy—one of those cohorts involves a combination with tiragolumab, an anti-TIGIT mAb. The gene discussed is TIGIT; the disease is hepatocellular carcinoma.